Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,501,522
  • Shares Outstanding, K 140,988
  • Annual Sales, $ 102,430 K
  • Annual Income, $ -95,190 K
  • 60-Month Beta 2.13
  • Price/Sales 14.27
  • Price/Cash Flow N/A
  • Price/Book 2.92
Trade SGMO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.24
  • Number of Estimates 6
  • High Estimate -0.10
  • Low Estimate -0.32
  • Prior Year -0.24
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.14 +16.52%
on 10/02/20
11.61 -8.27%
on 10/14/20
+0.14 (+1.33%)
since 09/22/20
3-Month
9.14 +16.52%
on 10/02/20
13.20 -19.32%
on 08/19/20
-0.48 (-4.31%)
since 07/22/20
52-Week
4.81 +121.41%
on 03/17/20
13.20 -19.32%
on 08/19/20
+2.02 (+23.41%)
since 10/22/19

Most Recent Stories

More News
Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises

PALM BEACH,  Fla., /PRNewswire/ -- The number of new cases of brain cancer across the world has been growing consistently for years and it is projected to continue on this upward path, which leads to...

MBRX : 0.7686 (-0.29%)
SURF : 8.83 (-0.67%)
GSK : 35.09 (-0.74%)
MRK : 79.21 (+1.46%)
SGMO : 10.65 (+2.70%)
PFE : 37.43 (+0.94%)
NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

AGYS : 26.15 (+1.99%)
NTLA : 24.81 (+5.62%)
EDIT : 32.26 (+6.56%)
CRSP : 90.16 (-2.23%)
SGMO : 10.65 (+2.70%)
HEAR : 18.76 (+4.34%)
JPM : 102.88 (+3.53%)
C : 43.95 (+2.19%)
BAC : 24.87 (+3.41%)
GS : 205.40 (+1.23%)
MS : 51.77 (+2.76%)
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene...

PFE : 37.43 (+0.94%)
SGMO : 10.65 (+2.70%)
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:

SGMO : 10.65 (+2.70%)
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors....

SGMO : 10.65 (+2.70%)
CRISPR Stocks: Buy or Trade?

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

VRTX : 210.08 (-0.62%)
SGMO : 10.65 (+2.70%)
EDIT : 32.26 (+6.56%)
NTLA : 24.81 (+5.62%)
CRSP : 90.16 (-2.23%)
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:

MS : 51.77 (+2.76%)
WFC : 23.25 (+2.42%)
SGMO : 10.65 (+2.70%)
Another Session of New Highs for the NASDAQ and S&P

Another Session of New Highs for the NASDAQ and S&P

SGMO : 10.65 (+2.70%)
LINC : 5.34 (-1.48%)
SQQQ : 21.75 (-0.05%)
LOGI : 89.09 (-3.36%)
AAPL : 115.75 (-0.96%)
UCO : 28.15 (+2.59%)
JO : 32.16 (+2.68%)
PDD : 87.77 (-2.73%)
TIF : 122.65 (-0.12%)
NFLX : 485.23 (-0.78%)
YNDX : 58.00 (+1.36%)
FB : 278.12 (-0.22%)
AMZN : 3,176.40 (-0.27%)
GOOG : 1,615.33 (+1.38%)
CRM : 249.67 (-1.79%)
AMGN : 227.98 (-0.43%)
HON : 176.85 (+2.30%)
XOM : 34.86 (+5.13%)
PFE : 37.43 (+0.94%)
RTX : 62.80 (+4.06%)
Sangamo Therapeu Shares Up 7.6% Since SmarTrend's Buy Recommendation (SGMO)

SmarTrend identified an Uptrend for Sangamo Therapeu (NASDAQ:SGMO) on July 8th, 2020 at $10.58. In approximately 2 months, Sangamo Therapeu has returned 7.61% as of today's recent price of $11.38.

SGMO : 10.65 (+2.70%)
BioMarin Down on CRL From FDA for Hemophilia A Candidate

BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.

PFE : 37.43 (+0.94%)
BMRN : 79.17 (+2.15%)
SGMO : 10.65 (+2.70%)
QURE : 41.26 (+4.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

2nd Resistance Point 11.21
1st Resistance Point 10.93
Last Price 10.65
1st Support Level 10.41
2nd Support Level 10.17

See More

52-Week High 13.20
Last Price 10.65
Fibonacci 61.8% 9.99
Fibonacci 50% 9.00
Fibonacci 38.2% 8.01
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar